Zenas BioPharma Strengthens Executive Leadership with Appointment of Jennifer Fox as Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., PhD. as Head of R&D and Chief Medical Officer

Expanded strategic and operational leadership positions Zenas for growth as obexelimab advances in late-stage clinical trials for multiple potential I&I indications

WALTHAM, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) —  Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology (I&I) directed therapies, today announced the appointment of Jennifer Fox as its Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., Ph. D as Head of Research and Development and Chief Medical Officer.

“We are thrilled to welcome Tanya and Jen to our executive team,” said Lonnie Moulder, Founder and Chief Executive Officer of Zenas BioPharma. “Tanya is a deeply experienced physician-scientist leader and Jen is a seasoned healthcare finance and corporate development leader. With their decades of industry leadership experience, they will each be an invaluable addition to Zenas as we head into our next phase of growth, advancing multiple global programs in late-stage clinical development with a goal to deliver differentiated I&I directed therapies to patients in need around the world.”

Ms. Fox is an experienced finance and corporate development executive with an extensive track record in corporate finance and healthcare investment banking, advising numerous private and public companies with respect to strategy, financings and mergers and acquisitions. Prior to joining Zenas, Ms. Fox served as Chief Financial Officer at Nuvation Bio, a publicly traded biotechnology company. She previously served as a Managing Director and Co-Head of North America Healthcare Corporate and Investment Banking Group at CitiGroup. Prior to CitiGroup, Ms. Fox held senior positions in investment banking at Deutsche Bank, Bear Stearns, Bank of America and Prudential Securities. She holds B.S. degrees in finance and marketing from Manhattan College.

Dr. Fischer is a physician-scientist with deep experience in academia and at both pharmaceutical and biotechnology companies, leading early and late-stage research and development programs across multiple therapeutic areas, including neurology and rare diseases. Prior to joining Zenas, she served as Chief Development Officer and Head of Translational Medicine at Biohaven, a publicly traded biopharmaceutical company. Dr. Fischer began her industry career at Bristol Myers Squibb and held R&D leadership roles of increasing responsibility at EMD-Serono, Sanofi-Genzyme and Alnylam. She is a neurologist and held appointments at Yale University School of Medicine following the completion of her Neurology residency at Yale New Haven Hospital. She obtained MD and PhD degrees from the University of Medicine and Dentistry of New Jersey – Robert Wood Johnson Medical School and Rutgers University, respectively, and was awarded the prestigious Presidential Early Career Award for Scientists and Engineers (PECASE).

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology (I&I) directed therapies for patients in need around the world. With clinical development capabilities and operations globally, Zenas is advancing a portfolio of potentially differentiated autoimmune therapeutics in areas of high unmet medical need. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.

About Obexelimab

Obexelimab is an investigational Phase 3-stage, bifunctional, non-cytolytic, humanized monoclonal antibody that mimics the action of antigen-antibody complexes by binding CD19 and FcγRIIb to inhibit B-lineage cell activity. In several early-stage clinical studies, including in various autoimmune diseases, 198 subjects were treated with obexelimab. In these clinical studies, obexelimab demonstrated inhibition of B cell function without depleting the cells, resulting in encouraging treatment effect in patients with various autoimmune diseases. Zenas acquired exclusive worldwide rights to obexelimab from Xencor, Inc. Obexelimab is currently being studied in a global Phase 3 clinical study in patients with IgG4 Related Disease and a global Phase2/3 study in patients with warm autoimmune hemolytic anemia (wAIHA). Clinical development of obexelimab for Multiple Sclerosis and Systemic Lupus Erythematosus is under evaluation.

More information on the Phase 3 (INDIGO) study for the treatment of IgG4 Related Disease is available at clinicaltrials.gov: NCT05662241. More information on the Phase 3 (SApHiAre) study for the treatment of wAIHA is available at clinicaltrials.gov: NCT05786573.

Investor and Media Contact:
Joe Farmer, President & COO
Zenas BioPharma
IR@zenasbio.com

GlobeNewswire Distribution ID 8987984

پہلی بین الاقوامی وائٹ ٹی کانفرنس کا آغاز، فڈنگ  بحیثیت بین الاقوامی وائٹ ٹی کانفرنس کا واحد

فڈنگ ، چین، 4 دسمبر 2023ء/سنہوا-ایشیانیٹ/– 30 نومبر کو پہلی بین الاقوامی وائٹ ٹی کانفرنس “فڈنگ، سفید چائے کی جائے پیدائش، ایک ساتھ جیت نے والے مستقبل کی تعمیر” کے عنوان سے پہلی بین الاقوامی وائٹ ٹی کانفرنس کا انعقاد کیا گیا۔ کانفرنس میں اقوام متحدہ کے مختلف اداروں کے نمائندگان، بین الاقوامی چائے کے شعبے کے ماہرین اور اسکالرز، معروف کاروباری شخصیات، سفارت خانے کے نمائندگان، چائے پیدا کرنے والے بڑے علاقوں کے سربراہان اور خریداروں کے نمائندوں سمیت دیگر معزز مہمانوں نے شرکت کی۔ فڈنگ سٹی کنورجنس میڈیا سینٹر کے مطابق توقع ہے کہ اس تقریب سے تعاون کے لیے عالمی سطح پر باہمی رابطے پر اتفاق رائے پیدا ہوگا اور وائٹ ٹی کو عالمی سطح پر لے جانے کے لیے ایک نیا خاکہ تیار کیا جائے گا۔

پہلی بین الاقوامی وائٹ ٹی کانفرنس

افتتاحی تقریب میں ، فڈنگ سٹی کو بین الاقوامی چائے کمیٹی اور چائنا چیمبر آف کامرس آف امپورٹ اینڈ ایکسپورٹ آف فوڈسٹف، دیسی پیداوار اور جانوروں کی ذیلی مصنوعات (سی ایف این اے) نے بین الاقوامی وائٹ ٹی کانفرنس کے واحد میزبان کے طور پر نامزد کیا تھا۔ یہ فڈنگ سٹی کے لئے ایک اور باوقار اعزاز ہے کیونکہ اسے دنیا کی سفید چائے کی جائے پیدائش اور دنیا کی سفید چائے کی ثقافت کی صنعت اور سائنس اور ٹیکنالوجی مرکز کا نام دیا گیا تھا۔

اس تقریب کی منصوبہ بندی یونیسکو، یونیڈو اور ایف اے او بین الحکومتی گروپ (آئی جی جی) کی رہنمائی میں کی گئی تھی، جس کی میزبانی سی این ایف اے اور انٹرنیشنل ٹی کمیٹی نے مشترکہ طور پر کی تھی، اور سی این ایف اے ٹی کمیٹی اور فڈنگ سٹی لیڈرشپ گروپ آن ٹی انڈسٹری ڈیولپمنٹ نے مشترکہ طور پر منعقد کیا تھا۔

ماخذ: فائڈنگ سٹی کنورجینس میڈیا سینٹر

تصویری منسلکات لنکس:https://iop.asianetnews.net/view-attachment?attach-id=443564

The First International White Tea Conference Kicks Off, Fuding as the sole host of the International White Tea Conference

FUDING, China, Dec. 4, 2023 /Xinhua-AsiaNet/– On November 30, themed “Fuding, the Birthplace of White Tea, Building A Win-win Future Together”, the first International White Tea Conference was held in Fuding City. Representatives from various United Nations agencies, experts and scholars from the international tea sector, leading entrepreneurs, embassy representatives, heads of major tea-producing regions and buyer representatives, among other distinguished guests attended the Conference. The event is expected to generate a consensus on global interconnectivity for cooperation, and to chart a new blueprint for Fuding White Tea to go global, according to Fuding City Convergence Media Center.

The first International White Tea Conference

At the opening ceremony, Fuding City was designated by the International Tea Committee and the China Chamber of Commerce of Import & Export of Foodstuffs, Native Produce & Animal By-products (CFNA) as the sole host of the International White Tea Conference. This is another prestigious honor for Fuding City after it was named the birthplace of the world’s white tea and the world’s white tea culture industry and science and technology center.

The event was planned under the guidance of UNESCO, UNIDO and FAO Intergovernmental Group (IGG) on Tea, co-hosted by CNFA and the International Tea Committee, and co-organized by the CNFA Tea Committee and the Fuding City Leadership Group on Tea Industry Development.

Source: Fuding City Convergence Media Center

Image Attachments Links: https://iop.asianetnews.net/view-attachment?attach-id=443564

 

Barbara and Peter, the first-ever female and male T.rex on show together, break all records

Seven Dials City: Media Snippet

A Media Snippet accompanying this announcement is available by clicking on this link.

  • Most successful dinosaur exhibit of all-time
  • More than 1.5 million visitors see Barbara and Peter – a world-first male & female T. rex pairing
  • Barbara is one of only three female T. rex specimens ever discovered
  • Auckland Museum breaks new ground by open access publication of scientific research of the specimens
  • Visitor numbers equivalent to a third of the population of New Zealand have seen the Barbara and Peter T. rex exhibit

AUCKLAND, New Zealand and LONDON, Dec. 04, 2023 (GLOBE NEWSWIRE) — With just days left to run, the world’s first display of an adult male and female T.rex side by side is believed to be the most successful dinosaur exhibition of all time.

Already, 1.5 million people have visited Auckland Museum to see this spectacular exhibition, which has run for a year, and which will draw to a close on December 10, 2023. Given that New Zealand itself has a population of just 5.1 million inhabitants, the numbers who came to see the two T.rex dinosaurs, named Barbara and Peter, are unprecedented.

David Reeves, CEO of Auckland Museum, hailed the impact of the exhibition: “Not only have we seen visitor numbers equivalent to almost the whole of Auckland’s population of 1.6 million come through the doors, but Barbara and Peter have provided a once-in-a-lifetime, educational experience for many, many thousands of school children. It has been a joy to see people’s reactions as they encounter these magnificent specimens for the first time.”

Tyrannosaurus rex fossils are extremely rare, with only about 20 T. rex on display in museums worldwide. These were the first T. rex exhibits in the Southern Hemisphere. The world’s most famous dinosaur is so scarce that there is no T. rex on permanent exhibit in the Middle East, the whole of Asia, Africa or Latin America. There are only four T. rex on display in Europe.

Female T. rex specimens are rarer still, with Barbara representing only the third ever pregnant Tyrannosaurus rex dinosaur skeleton to be discovered. Barbara is 44.7 per cent complete, making her the 8th most complete T. rex in the world. She measures an impressive 11.7 metres long and 3.4m high.

Close viewing of the T.rex reveals some of the incredible anatomical features of one of the largest land predators of all time and offers the ability to inspect injuries that pathological findings revealed, specifically an injury to Barbara’s leg, likely to have been caused by another T.rex. It is remarkable that a massive animal like Barbara, which relied on walking or running on two legs as the primary method of locomotion, could survive such an injury. She lived for a long period after the injury, as can be seen by the evidence of a healed metatarsal.

Dr Andre Lujan, President of the Association of Applied Paleontological Sciences, said: “The Auckland Museum should be congratulated on this ground-breaking world first exhibit of a male and female T.rex together. Visitor numbers show that a huge percentage of New Zealand’s children got to see these magnificent specimens, which is a wonderful inspiration for the next generation of paleontologists.”

Alongside the exhibiting of Barbara and Peter, Auckland Museum has made public the preliminary scientific research on the specimens, undertaken by expert academics. According to David Reeves: “The publication of this research, made available to the museum and its visitors, is a novel and hugely important concept, designed to bridge the gap for the lay observer between the learned, peer-reviewed academic reports and the very limited data typically supplied to visitors by museums in support of such exhibits. This has truly ignited the imagination of young scientists in New Zealand.”

These preliminary reports have been prepared by two of the world’s top theropod paleontologists, Dr David Burnham (University of Kansas Biodiversity Institute and Natural History Museum) and Dr John Nudds (Department of Earth and Environmental Sciences, University of Manchester), who studied both Barbara and Peter in their university laboratories for many months.

Dr Nudds commented: “These reports are designed to encourage children and young people to learn about the extraordinary world of theropods, a subject that has fascinated me for my entire professional life.”

Dr Burnham added: “Barbara and Peter each represents an individual animal that was a living and breathing organism. Studying and reporting publicly about each individual specimen means it becomes part of the entire body of knowledge about Tyrannosaurus rex. Therefore, every documented specimen counts enormously, not least because there are so very few.”

This unique display, together with published research, has afforded the public to gain a deeper understanding of the history and mysteries of the T.rex, providing insights into their origins, lives, and the remarkable process of finding and mounting fossil specimens.

The exhibition will close soon, but already 1.5 million people have been thrilled by the once-in-a-lifetime opportunity to stand face-to-face with two real T. rex, brought together for the first time in 66 million years.

For further information

Seven Dials City

Simon Kelner
simon@sevendialspr.com
+44 7775 788898

James Devas
james@sevendialscity.com
+44 7885 813 114

ABOUT AUCKLAND WAR MEMORIAL MUSEUM

Auckland War Memorial Museum is one of New Zealand’s first museums. The Museum tells the story of New Zealand, its place in the Pacific and its people. The Museum is a war memorial for the province of Auckland and holds one of New Zealand’s top three heritage libraries. It has pre-eminent Māori and Pacific collections, significant natural history resources and major social and military history collections, as well as decorative arts and pictorial collections.

GlobeNewswire Distribution ID 1000902476

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Paycom Software, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – PAYC

NEW YORK, Dec. 03, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Paycom Software, Inc. (NYSE: PAYC) between May 3, 2023 and November 1, 2023, both dates inclusive (the “Class Period”), of the important January 9, 2024 lead plaintiff deadline in the securities class action commenced by the Firm.

SO WHAT: If you purchased Paycom securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Paycom class action, go to https://rosenlegal.com/submit-form/?case_id=20233 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 9, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Paycom’s Beti product led to cannibalization of the Company’s services and revenues; (2) Paycom knew but failed to disclose that Beti was leading to cannibalization of Paycom’s services and revenues, and failed to warn of cannibalization as a general risk; (3) as a result of cannibalization of revenue, Paycom missed its expected third quarter 2023 revenue and would have to revise its expected 2023 revenues; (4) the cannibalization issue resulted in projected 2024 year-over-year revenue growth to between 10% and 12%, well below expectations; and (5) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Paycom class action, go to https://rosenlegal.com/submit-form/?case_id=20233 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8988386

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages SunPower Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPWR

NEW YORK, Dec. 03, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SunPower Corporation (NASDAQ: SPWR) between March 9, 2023 and October 24, 2023, both dates inclusive (the “Class Period”), of the important December 26, 2023 lead plaintiff deadline.

SO WHAT: If you purchased SunPower securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the SunPower class action, go to https://rosenlegal.com/submit-form/?case_id=20033 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 26, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made materially false and/or misleading statements and/or failed to disclose that: (1) due to a material weakness in its internal control over financial reporting, SunPower had inaccurately reported cost of revenue and inventory metrics; (2) as a result of the foregoing, SunPower was reasonably likely to incur significant charges to restate prior reporting; and (3) as a result of the foregoing, defendants’ positive statements about SunPower’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the SunPower class action, go to https://rosenlegal.com/submit-form/?case_id=20033 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8988407